Market Capitalization

A new settlement positions a cost-effective alternative to the blockbuster eye drug Eylea for a 2026 U.S. launch, signaling intense market disruption.

Newly public AI firm Fusemachines unveils an ambitious 2026 growth plan, but faces significant financial hurdles and deep investor skepticism.

As Simply Good Foods preps its Q1 report, investors weigh Quest's strong growth against the ongoing struggles of its Atkins brand and market pressures.

The Nasdaq-listed restaurant operator confirms its board and auditor, signaling stability as it navigates a volatile stock performance and dynamic F&B sector.

A decade-long wait ends as the FDA approves a new 1st-line therapy for HER2+ breast cancer. See how ENHERTU reshapes patient outcomes and market dynamics.

Cerro de Pasco Resources locks in a vital community deal in Peru, a key step in a $400M plan to turn a century of mining waste into a profitable venture.

AMTD Digital's subsidiary is on a global hotel buying binge, but a history of extreme stock volatility and underlying financial risks raise serious questions.

BlackRock's latest fund distributions reveal a heavy reliance on 'return of capital,' especially in its resource funds. What does this mean for investors?

This REIT's stock is worth millions, but it claims its apartments are worth much more. Can a bold strategic review unlock this hidden value for investors?

Aligos Therapeutics is using strategic stock grants to lure top talent. Is this a savvy growth play or a creeping cost for shareholders? We break it down.

Lument Finance Trust's latest dividend boasts an attractive yield, but recent adjustments raise questions about the health of commercial real estate.

MMTEC dodged delisting, but a one-year Nasdaq monitor and a history of reverse splits raise questions about its long-term viability on US exchanges.

Cadrenal Therapeutics acquires a novel Phase 2 drug for a deadly clotting disorder, a strategic move targeting an underserved $1 billion market.

Impressive drill results from Lapon Canyon are turning heads, but the discovery of monzonite-hosted gold suggests a much larger story is unfolding.

As lithium fire risks escalate, a small-cap firm's live EV burn demo in Houston draws industry giants, signaling a pivotal moment for safety tech.

BlockQuarry unveils a sleek new website for its US-made miner, but can this digital pivot overcome steep financial hurdles and disrupt a crowded market?

Quantum Computing Inc. is leaving the lab for Las Vegas, betting its US-made photonic chips can solve real-world AI problems and justify a lofty valuation.

The space firm secures vital cash through a complex warrant deal, but at what cost to shareholders? All eyes are now on a critical investor vote.

As drone attacks paralyze European airports, an Israeli tech firm's 'soft kill' net system emerges as a key contender for NATO's defense strategy.

Following stellar clinical data, Terns Pharmaceuticals' upsized $650M offering signals massive investor confidence and funds its push to disrupt the CML market.